Table 2.
Summary of outcomes in the selected RCTs.
| First Author (Year) | Median OS (Months) | HR (95% CI) for OS | Median PFS (Months) |
HR (95% CI) for PFS | ORR | Severe Adverse Event |
|---|---|---|---|---|---|---|
| Andtbacka 2015 [26] | EG: 23.3 CG: 18.9 |
0.79 (0.62, 1.00) |
NR | NR | EG: 78 CG: 8 |
EG:105 CG: 27 |
| Bernstein 2018 [28] | EG: 17.4 CG: 10.4 |
0.61 (0.33, 1.12) |
EG: 3.78 CG: 3.38 |
1.11 (0.64, 1.92) |
EG: 9 CG: 9 |
EG: 18 CG: 18 |
| Bradbury 2018 [29] | EG: 7.8 CG: 7.4 |
0.98 (0.72, 1.34) |
EG: 3.0 CG: 2.8 |
0.90 (0.65, 1.25) |
EG: 11 CG: 11 |
NR |
| Chesney 2018 [27] | NR | 0.80 (0.44, 1.46) |
EG: 8.2 CG: 6.4 |
0.83 (0.56, 1.23) |
EG: 38 CG: 18 |
EG: 43 CG: 33 |
| Cohn 2017 [30] | EG: 12.6 CG: 13.1 |
1.01 (0.64, 1.58) |
EG: 4.4 CG: 4.3 |
1.11 (0.64, 1.91) |
EG: 8 CG: 9 |
NR |
| Eigl 2018 [31] | NR | 1.86 (0.97, 3.57) |
NR | NR | EG: 11 CG: 18 |
NR |
| Freytag 2014 [34] | No death | NR | No death | NR | NR | EG: 1 CG: 1 |
| Jonker 2018 [32] | EG: 19.2 CG: 20.1 |
1.18 (0.75, 1.87) |
EG: 7.33 CG: 9.13 |
1.65 (1.02, 2.67) |
EG: 27 CG: 18 |
NR |
| Moehler 2019 [35] | EG: 4.2 CG: 4.4 |
1.19 (0.77, 1.83) |
EG: 4.94 CG: 5.2 |
NR | EG: 0 CG: 0 |
EG: 45 CG: 7 |
| Noonan 2016 [33] | EG: 7.31 CG: 8.77 |
1.12 (0.66, 1.91) |
EG: 1.7 CG: 1.7 |
0.86 (0.52, 1.43) |
EG: 7 CG: 7 |
NR |
| Schenk 2020 [19] | EG: 6.6 CG: 13.2 |
1.49 (0.77, 2.87) |
NR | 1.03 (0.58, 1.83) |
EG: 1 CG: 4 |
EG: 9 CG: 5 |
EG, experimental group; CG, control group; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; NR, not reported; CI, confidence interval.